Samsung Electronics announced on Wednesday that it will participate in an expanded Series E funding round for the U.S. genomics technology company Element Biosciences, investing an additional $175 million to become its largest shareholder.

In a press release, Samsung Electronics Co., Ltd. stated that this investment represents a further strategic commitment, following its participation in Element Biosciences' Series D funding round in July 2024.

Element Biosciences, headquartered in San Diego, California, is focused on developing next-generation DNA sequencing and multi-omics platforms for biomedical research, drug development, clinical studies, agriculture, and other life science fields.

Samsung Electronics Co., Ltd. indicated that this investment aligns with its strategic objective of expanding its business into the precision medicine and digital health technology sectors.

Tae-moon Roh, co-CEO of Samsung's mobile business, said in a statement: "The combination of Samsung Electronics' expertise in AI, medical devices, and digital health with Element's innovative genomic analysis technology holds the potential for synergistic effects that will help shape the future of personalized medicine."

Samsung emphasized that Element's next-generation gene sequencing technology and multi-omics capabilities are key areas of focus.

Multi-omics is a technology that enables the simultaneous analysis of various types of biological data, including not only DNA but also RNA and proteins, providing a more comprehensive understanding of how genetic information functions within an organism.